《公司業績》信達生物(01801.HK)全年虧損收窄至9.98億元人幣 不派息
信達生物(01801.HK)公布截至去年12月底止全年業績,營業額38.44億元人民幣(下同),按年升266.9%。虧損收窄至9.98億元,上年同期蝕17.2億元;每股虧損0.74元。不派息。
按非國際財務報告準則計,年內經調整虧損及全面開支總額為5.96億元,按年減少9.98億元,主要由於總收入大幅增加,其部分由持續的研發投資及於商業化上的努力所抵銷。
產品收入達23.68億元,按年增長133%,主要由集團主導產品達伯舒(信迪利單抗注射液)的強勁按年增長,及三項新獲批准的抗體藥物於去年下半年所貢獻的收入帶動。產品銷售毛利率為83.6%,較2019年之87.7%微幅下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.